Gary Wilcox, Ph.D.
Vice Chairman and Interim Chief Executive Officer
Gary Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation (NASDAQ: ICOS) where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of directors. Prior to that, he served as Vice Chairman, Executive Vice President and a Director of Xoma Corporation (NASDAQ: XOMA). Prior to Xoma, Dr. Wilcox co-founded Ingene Inc. (NASDAQ: IGEI) serving as its Chairman, President and CEO prior to the merger of Ingene into Xoma. Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA for 10 years. He has served on 15 boards of directors including NASDAQ, New York and London stock exchange companies, as well as private technology companies.
Sam Lee, Ph.D.
Sam Lee has 20 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at Icos Corporation (NASDAQ: ICOS) where he was responsible for incorporating protein crystallography and structural screening technologies into Icos research. Additionally, Dr. Lee he played a key role for developing phosphoinositide 3-kinase (PI3K) delta inhibitors at Icos, which ultimately yielded an FDA approved product. He received his Ph.D. in Biological Sciences from the University of Notre Dame, and completed postdoctoral training in viral biochemistry with Dr. I. R. Lehman at Stanford. While at Stanford, Dr. Lee founded and was CEO of Viral Assays in Cupertino, CA.
James J. Martin
Chief Financial Officer
James Martin has 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to Cocrystal, Mr. Martin served as the Chief Financial Officer of Motus GI, a privately held medical device company. From September 2014 to November 2016 he served as the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.) (NASDAQ: VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015, Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (NASDAQ: VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2013, Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc. Prior to that Mr. Martin served as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc., (OTCPink:NIMU), a company marketing non-invasive medical devices. Mr. Martin holds an undergraduate degree in business administration and an MBA from Barry University in Miami. He is a Certified Public Accountant.